CYTOTOXICITY-INDUCING THERAPEUTIC AGENT
The present invention provides multispecific antigen-binding molecules that comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, uses of such multispecific antigen-binding molecules, etc. The presen...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
23.04.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides multispecific antigen-binding molecules that comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, uses of such multispecific antigen-binding molecules, etc. The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity and high stability, which comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing RNF43, it is possible to produce novel pharmaceutical compositions comprising the multispecific antigen-binding molecules for treating or preventing various cancers. |
---|---|
Bibliography: | Application Number: US201816605556 |